These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 1665123)

  • 81. The in-vitro activity of temafloxacin, against gram-positive bacteria.
    Mandell LA; Lawrence T; Rotstein C; Gorzynski EA; Beam TR; Amsterdam D
    J Antimicrob Chemother; 1991 Dec; 28 Suppl C():15-24. PubMed ID: 1664826
    [TBL] [Abstract][Full Text] [Related]  

  • 82. In vitro activity of moxifloxacin, a new 8-methoxyquinolone, against gram-positive bacteria.
    Malathum K; Singh KV; Murray BE
    Diagn Microbiol Infect Dis; 1999 Oct; 35(2):127-33. PubMed ID: 10579093
    [TBL] [Abstract][Full Text] [Related]  

  • 83. In-vitro postantibiotic effect of sparfloxacin and ciprofloxacin against Pseudomonas aeruginosa and Enterococcus faecalis.
    Pastor A; Pemán J; Cantón E
    J Antimicrob Chemother; 1994 Nov; 34(5):679-85. PubMed ID: 7706163
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Comparative in vitro activity of the new glycopeptide SK&F 104662 against problematic gram-positive bacteria.
    Soriano F; Zapardiel J; Fernández-Roblas R
    Eur J Clin Microbiol Infect Dis; 1991 Sep; 10(9):782-4. PubMed ID: 1810738
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Comparative in-vitro activity of sparfloxacin against genital pathogens.
    Perea EJ; Aznar J; Garcia-Iglesias MC; Pascual A
    J Antimicrob Chemother; 1996 May; 37 Suppl A():19-25. PubMed ID: 8737122
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Comparative in vitro activity of PD 127391, a new fluoroquinolone agent, against susceptible and resistant clinical isolates of gram-positive cocci.
    Miranda AG; Wanger AR; Singh KV; Murray BE
    Antimicrob Agents Chemother; 1992 Jun; 36(6):1325-8. PubMed ID: 1329621
    [TBL] [Abstract][Full Text] [Related]  

  • 87. In vitro activity of the new quinolone moxifloxacin (Bay 12-8039) against resistant gram-positive clinical isolates.
    Alcalá L; Cercenado E; García-Garrote F; Bouza E
    Diagn Microbiol Infect Dis; 1999 Jan; 33(1):27-31. PubMed ID: 9990472
    [TBL] [Abstract][Full Text] [Related]  

  • 88. In vitro activity of CI-934, a new quinolone antimicrobial, against gram-positive bacteria.
    Eliopoulos GM; Reiszner E; Caputo GM; Moellering RC
    Diagn Microbiol Infect Dis; 1986 Nov; 5(4):341-4. PubMed ID: 3096629
    [TBL] [Abstract][Full Text] [Related]  

  • 89. In-vitro activity of Sch 34343, a new penam, against gram-positive isolates from cancer patients.
    Rolston KV; Alvarez ME; Hoy JF; Alderman HC; Ho DH; Bodey GP
    J Antimicrob Chemother; 1986 Aug; 18(2):159-62. PubMed ID: 3093447
    [TBL] [Abstract][Full Text] [Related]  

  • 90. WIN 57273, a new fluoroquinolone with enhanced in vitro activity versus gram-positive pathogens.
    Kaatz GW; Seo SM
    Antimicrob Agents Chemother; 1990 Jul; 34(7):1376-80. PubMed ID: 2117417
    [TBL] [Abstract][Full Text] [Related]  

  • 91. SYN987, SYN1193, and SYN1253, new quinolones highly active against gram-positive cocci.
    Kitzis MD; Goldstein FW; Ishida N; Acar JF
    J Antimicrob Chemother; 1995 Jul; 36(1):209-13. PubMed ID: 8537267
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Pharmacodynamics of fluoroquinolones.
    Dalhoff A
    J Antimicrob Chemother; 1999 May; 43 Suppl B():51-9. PubMed ID: 10382876
    [TBL] [Abstract][Full Text] [Related]  

  • 93. In vitro activity of fleroxacin against aerobic gram-positive bacteria including Corynebacterium jeikeium.
    Hohl P; Felber AM
    Chemotherapy; 1990; 36(6):403-6. PubMed ID: 2127242
    [TBL] [Abstract][Full Text] [Related]  

  • 94. In-vitro activity of ciprofloxacin and sixteen other antimicrobial agents against blood culture isolates.
    Eltahawy AT
    J Chemother; 1993 Apr; 5(2):94-102. PubMed ID: 8515299
    [TBL] [Abstract][Full Text] [Related]  

  • 95. High-level gentamicin-resistant enterococci: in vitro activity of double and triple combinations of antimicrobial drugs.
    Ferrara A; Dos Santos C; Cimbro M
    Chemotherapy; 1996; 42(1):37-46. PubMed ID: 8751265
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Multicenter evaluation of the in vitro activities of three new quinolones, sparfloxacin, CI-960, and PD 131,628, compared with the activity of ciprofloxacin against 5,252 clinical bacterial isolates.
    Fuchs PC; Barry AL; Pfaller MA; Allen SD; Gerlach EH
    Antimicrob Agents Chemother; 1991 Apr; 35(4):764-6. PubMed ID: 2069384
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Bactericidal effect of sparfloxacin alone and in combination with amoxicillin against Streptococcus pneumoniae as determined by kill-kinetic studies.
    Barakett V; Lesage D; Delisle F; Richard G; Petit JC
    Infection; 1996; 24(1):22-5. PubMed ID: 8852458
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Studies of the killing kinetics of benzylpenicillin, cefuroxime, azithromycin, and sparfloxacin on bacteria in the postantibiotic phase.
    Odenholt I; Löwdin E; Cars O
    Antimicrob Agents Chemother; 1997 Nov; 41(11):2522-6. PubMed ID: 9371360
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Interpretive criteria for disk diffusion susceptibility testing of sparfloxacin.
    Kayser FH; Wüst J
    Eur J Clin Microbiol Infect Dis; 1991 Mar; 10(3):163-6. PubMed ID: 2060516
    [TBL] [Abstract][Full Text] [Related]  

  • 100. In vitro evaluation of difloxacin (A-56619), A-56620, and other 4-quinolones against isolates from cancer patients.
    Rolston KV; Ho DH; LeBlanc B; Bodey GP
    Chemotherapy; 1987; 33(6):419-27. PubMed ID: 3428009
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.